AU2002365291B2 - Pharmaceutical composition for inducing an immune response in a human or animal - Google Patents

Pharmaceutical composition for inducing an immune response in a human or animal Download PDF

Info

Publication number
AU2002365291B2
AU2002365291B2 AU2002365291A AU2002365291A AU2002365291B2 AU 2002365291 B2 AU2002365291 B2 AU 2002365291B2 AU 2002365291 A AU2002365291 A AU 2002365291A AU 2002365291 A AU2002365291 A AU 2002365291A AU 2002365291 B2 AU2002365291 B2 AU 2002365291B2
Authority
AU
Australia
Prior art keywords
mage
antigens
cancer
dendritic cells
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002365291A
Other languages
English (en)
Other versions
AU2002365291A1 (en
Inventor
Karine Djandjougazian
Alexei Kirkin
Jesper Zeuthen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enochian Biosciences Denmark ApS
Original Assignee
Dandrit Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dandrit Biotech AS filed Critical Dandrit Biotech AS
Publication of AU2002365291A1 publication Critical patent/AU2002365291A1/en
Application granted granted Critical
Publication of AU2002365291B2 publication Critical patent/AU2002365291B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002365291A 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal Expired AU2002365291B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200101770 2001-11-29
DKPA200101770 2001-11-29
US33670601P 2001-12-07 2001-12-07
US60/336,706 2001-12-07
PCT/DK2002/000802 WO2003045427A2 (en) 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal

Publications (2)

Publication Number Publication Date
AU2002365291A1 AU2002365291A1 (en) 2003-06-10
AU2002365291B2 true AU2002365291B2 (en) 2007-11-01

Family

ID=26069102

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002365291A Expired AU2002365291B2 (en) 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal

Country Status (11)

Country Link
US (2) US7771998B2 (enExample)
EP (1) EP1448229B1 (enExample)
JP (1) JP2005515192A (enExample)
AT (1) ATE446106T1 (enExample)
AU (1) AU2002365291B2 (enExample)
DE (1) DE60234115D1 (enExample)
DK (1) DK1448229T3 (enExample)
ES (1) ES2335396T3 (enExample)
IL (1) IL161832A0 (enExample)
RU (1) RU2313365C2 (enExample)
WO (1) WO2003045427A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
ES2294346T3 (es) * 2002-11-28 2008-04-01 Peter Kufer Rt-pcr en tiempo real novedosa para la deteccion sensible de multiples transcripciones del gen mage.
DE602005027738D1 (de) * 2004-11-18 2011-06-09 Univ Hiroshima Nat Univ Corp Verfahren und kit zur expression von protein unter regulation der expression von einer durch genamplifikation gebildeten wiederholungssequenz und transformant
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
BRPI0706784A2 (pt) 2006-01-30 2011-04-05 Ludwig Inst Cancer Res antìgeno de cáncer de testìculo ctsp
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
EP2154243B1 (en) 2007-05-17 2016-01-13 ID Pharma Co., Ltd. Method for production of dendritic cell
JP2011529080A (ja) * 2008-07-24 2011-12-01 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 癌幹細胞を標的とする治療法
BRPI0920679A2 (pt) * 2008-10-08 2022-05-17 Intrexon Corp Células construídas expressando múltiplos imunomoduladores e usos das mesmas
WO2011028531A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
MX362513B (es) * 2010-03-23 2019-01-22 Intrexon Corp Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos.
GB201013443D0 (en) * 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
UA116528C2 (uk) 2011-08-30 2018-04-10 Астекс Фармасьютікалз, Інк. Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування
CA2852967A1 (en) * 2011-10-20 2013-04-25 California Stem Cell, Inc. Antigen presenting cancer vaccine
JP5871228B2 (ja) * 2011-10-31 2016-03-01 国立大学法人佐賀大学 慢性副鼻腔炎の検出方法
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
WO2014007669A1 (ru) * 2012-07-04 2014-01-09 Volgushev Sergei Anatolievich Аутологичная клеточная вакцина для лечения онкологических заболеваний и способ ее получения
CN108024535A (zh) 2015-07-02 2018-05-11 大塚制药株式会社 冻干药物组合物
SG10202112047TA (en) 2015-09-18 2021-12-30 Baylor College Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
GB201520542D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.
KR20210044207A (ko) * 2018-07-15 2021-04-22 이노치안 바이오파마, 인코포레이티드 암 치료를 위한 재조합 수지상 세포를 사용하는 방법 및 조성물
EP3903811A1 (en) 2020-05-01 2021-11-03 R.G.C.C. Holdings AG Pharmaceutical composition and method for inducing an immune response
CA3119597C (en) 2020-10-12 2023-07-11 R.G.C.C. Holdings AG Sars-cov-2 vaccines
EP3981425A1 (en) 2020-10-12 2022-04-13 R.G.C.C. Holdings AG Sars-cov-2 vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
WO2001041787A1 (en) 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
AU2002252268B2 (en) 2001-03-09 2007-01-18 Baylor Research Institute Method of treating malignancies through induction of blood immune responses

Also Published As

Publication number Publication date
RU2313365C2 (ru) 2007-12-27
EP1448229B1 (en) 2009-10-21
AU2002365291A1 (en) 2003-06-10
DK1448229T3 (da) 2010-03-08
WO2003045427A3 (en) 2004-03-25
US7723107B2 (en) 2010-05-25
JP2005515192A (ja) 2005-05-26
WO2003045427A2 (en) 2003-06-05
US20060051324A1 (en) 2006-03-09
RU2004119548A (ru) 2005-03-27
ATE446106T1 (de) 2009-11-15
DE60234115D1 (de) 2009-12-03
IL161832A0 (en) 2005-11-20
ES2335396T3 (es) 2010-03-26
HK1086750A1 (zh) 2006-09-29
US20090029457A1 (en) 2009-01-29
EP1448229A2 (en) 2004-08-25
US7771998B2 (en) 2010-08-10

Similar Documents

Publication Publication Date Title
US7723107B2 (en) Pharmaceutical composition for inducing an immune response in a human or animal
Mukherji et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.
JP5452231B2 (ja) 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン
AU2002334387B2 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
Wu et al. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas
AU2002334387A1 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
US20140234350A1 (en) Ovarian cancer vaccines and vaccination methods
CN101861163B (zh) 用于治疗黑素瘤的细胞系、含有它们的组合物、制备所述组合物的方法以及治疗方法
CN100558400C (zh) 诱导人或动物免疫应答的药物组合物
Vichchatorn et al. Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme
AU779325B2 (en) Melanoma vaccine and methods of making and using same
HK1086750B (en) Pharmaceutical composition for inducing an immune response in a human or animal
US20030185808A1 (en) Prostate cell lines
Koide et al. Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70
Soruri et al. In vitro generation of cytolytic T cells against human melanoma cells overexpressing HDM2
KR20110128008A (ko) Ｒｎａ 전이 항원 제시 세포를 이용한 신규 종양항원의 규명 방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired